Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Value chain filling

MyoContract AG and Graffinity AG hope that by merging to create Santhera AG, with discovery capabilities and a late-stage clinical program, they will be able to attract significantly more investors and possibly be ready for an IPO in about 12 months.

The merged entity combines Graffinity's fragment-based discovery platform and preclinical pipeline

Read the full 517 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers